Меню
Набор скоро начнётся NCT07222813

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

Без фазы С лечением Heart Failure Heart Failure - NYHA II - IV

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: FibroScan, Right-sided Heart Catheterization, Transthoracic echocardiography, Blood Sample Analysis.
Кому может быть актуально
Состояния в реестре: Heart Failure, Heart Failure - NYHA II - IV. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США, Франция, Германия, Польша
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Performance of Liver Stiffness Measurement (LSM) by FibroScan® for the Diagnosis of Elevated Central Venous Pressure (CVP)

Обзор

This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.

Подробное описание

CHF, as defined by the American College of Cardiology and the American Heart Association, is "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood." These patients will often develop congestion that may require urgent hospitalization, especially if pulmonary congestion is present. However, congestion can be difficult to assess, especially when symptoms are mild, or in patients nearing discharge from an HF hospitalization.8 Increased cardiac filling pressures, including the CVP, often silently precede the appearance of congestive symptoms by days resulting in hepatic congestion.

Invasive methods, such as RHC, remain the gold standard method of measuring CVP, offering accurate and direct hemodynamic data. However, RHC requires specialized training and invasive vascular access and is associated with procedural risks including bleeding, infection, arrhythmia, and patient discomfort.

Echocardiography is the most common non-invasive adjunct tool for estimating CVP and assessing cardiac function. It evaluates indirect parameters, right atrial size, IVC diameter, and collapsibility to detect elevated CVP.

LSM by VCTE™ has emerged as a novel non-invasive approach to detecting elevated CVP indirectly. Liver elastography relies on imaging techniques to assess LSM, with high values equating to increased stiffness. While this was developed to assess fibrosis in chronic liver diseases, LSM also reflects increased CVP and hepatic congestion. Multiple studies have shown promising correlations between increased liver stiffness and invasively measured CVP, indicating a potential clinical strategy for detecting hemodynamic congestion non-invasively.

Given these considerations, the current clinical investigation aims to evaluate the 13.3 kPa cutoff performance of LSM with FibroScan (Echosens, Paris, France) to diagnose elevated CVP (\>10 mm Hg).

Вмешательства

  • Устройство FibroScan
    At Day 0: 1 FibroScan examination to collect Liver Stiffness Measurement (LSM)
  • Процедура Right-sided Heart Catheterization
    at Day 0: Right-sided Heart Catheterization (RHC) to measure Central Venous Pressure (CVP)
  • Процедура Transthoracic echocardiography
    at Day 0 assessment of cardiac function
  • Биопрепарат Blood Sample Analysis
    At Day0: To assess baseline organ function that may impact participant safety, and blood samples for clinical laboratory tests

Первичные конечные точки

  • Proportion of individuals with elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Sensitivity] [Срок оценки: at Day 0]
  • Proportion of individuals without elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Specificity] [Срок оценки: at Day 0]
Вторичные конечные точки (8)
  • Proportion of individuals correctly identified by LSM (Youden index) for the diagnosis of elevated CVP (>10 mm Hg) [Срок оценки: at Day 0]
  • Proportion of individuals correctly identified by LSM (Youden index) for the diagnosis of abnormal IVC diameter [Срок оценки: at Day 0]
  • Logistic regression model to identify clinical, laboratory, and echocardiographic factors associated with LSM/CVP discordance. [Срок оценки: at Day 0]
  • Correlation between LSM and echocardiographic parameters evaluated with Pearson or Spearman correlation coefficients [Срок оценки: at Day 0]
  • Correlation between LSM and NT-proBNP evaluated with Pearson or Spearman correlation coefficients [Срок оценки: at Day 0]
  • Correlation between LSM and CA-125 evaluated with Pearson or Spearman correlation coefficients [Срок оценки: at Day 0]
  • Correlation between LSM and clinical parameters evaluated with Pearson or Spearman correlation coefficients [Срок оценки: at Day 0]
  • Proportion of individuals correctly identified for the diagnosis of elevated CVP (>10 mm Hg) compared between LSM, echocardiography parameter and NT-proBNP using DeLong's test for correlated ROC curves [Срок оценки: at Day 0]

Критерии участия

Критерии включения

  • Have read, understood, and signed the informed consent form (ICF)
  • Be ≥18 years of age at the time of screening
  • Have suspected or diagnosed acute or chronic HF and be scheduled to undergo right-sided cardiac catheterization

Критерии исключения

  • Inability to consent
  • Chronic liver disease (self-reported alcohol use >14 drinks/week in females and >21 drinks/week in males), positive hepatitis C virus serology, positive hepatitis B surface antigen, autoimmune hepatitis, hemochromatosis, or cholestatic disease)
  • BMI >40 kg/m2
  • Fontan-type circulation
  • Ascites
  • Heart transplantation
  • Pregnancy, breastfeeding, or intent to become pregnant during the study
  • Intent to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Диагностика

Центры проведения

США · 4 центра
  • Keck Medicine of USC-Norris Healthcare Center - Transplant Clinic — Los Angeles
  • University of Minnesota — Minneota
  • Medical University of South Carolina — Charleston
  • University of Texas Southwestern Medical Center - Clinical Heart and Vascular Center - Wes — Dallas
Франция · 1 центр
  • Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou — Rennes
Германия · 1 центр
  • Deutsches Herzzentrum der Charité (DHZC) - Klinik fuer Herz-, Thorax- und Gefaesschirurgie — Berlin
Польша · 1 центр
  • Uniwersytet Medyczny im. Piastow Slaskich we Wroclawiu, Instytut Chorob Serca — Wroclaw

Идентификаторы

NCT: NCT07222813 · Cs002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗